<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112707</url>
  </required_header>
  <id_info>
    <org_study_id>012017POEM</org_study_id>
    <nct_id>NCT03112707</nct_id>
  </id_info>
  <brief_title>Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT</brief_title>
  <acronym>POEM</acronym>
  <official_title>Performance of Bioresorbable Polymer-Coated Everolimus-Eluting Synergy® Stent in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Revascularization Followed by 1-Month Dual Antiplatelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanitas Hospital, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanitas Hospital, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the safety of bioresorbable polymer-coated everolimus-eluting Synergy®&#xD;
      stent followed by 1-month dual antiplatelet therapy in patients at high-bleeding risk.&#xD;
&#xD;
      Study population: Real world high-bleeding risk (HBR) patients with coronary artery disease&#xD;
      (stable as well as acute coronary syndromes) who qualify for percutaneous coronary&#xD;
      interventions.&#xD;
&#xD;
      Study size: A total of 1023 patients will be enrolled. Study design: Prospective, single-arm,&#xD;
      multicentre trial, powered for non-inferiority with respect to objective performance criteria&#xD;
      (OPC).&#xD;
&#xD;
      Antiplatelet therapy: Dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor&#xD;
      for a duration of 1 month, after which single antiplatelet therapy with aspirin will be&#xD;
      recommended indefinitely. In case of need for oral anticoagulation, patients will receive an&#xD;
      oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.&#xD;
&#xD;
      Primary endpoint: Composite of cardiac death, myocardial infarction, or definite/probable&#xD;
      stent thrombosis at 1-year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>1 year</time_frame>
    <description>Composite of cardiac death, myocardial infarction, and definite/probable stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Myocardial infarction (defined according to III universal definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Stent thrombosis (defined according to ARC criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target-vessel revascularization</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Target-vessel revascularization (any and clinically driven)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target-lesion revascularization</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Target-lesion revascularization (any and clinically driven)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Major bleeding (BARC 3 to 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular event</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Cerebrovascular event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target-lesion failure</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>composite of cardiac death, target-vessel myocardial infarction, or clinically-driven target-lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient oriented composite endpoint</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Composite of any death, any MI, any revascularization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1023</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P2Y12 inhibitor</intervention_name>
    <description>After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients will need to have symptomatic coronary artery disease including patients with&#xD;
        chronic stable angina, silent ischemia, or acute coronary syndromes (including NSTE-ACS and&#xD;
        STE-ACS) and presence of one or more coronary artery stenoses &gt;50% in a native coronary&#xD;
        artery or a saphenous bypass graft that treated with one or multiple Synergy® stents.&#xD;
&#xD;
        Moreover, in order to be included patients will need to meet at least 1 of the following&#xD;
        HBR criteria:&#xD;
&#xD;
          1. Age ≥75 years&#xD;
&#xD;
          2. Oral anticoagulation planned to continue after PCI&#xD;
&#xD;
          3. Hemoglobin &lt;11 g/l,&#xD;
&#xD;
          4. Transfusion within 4 week before inclusion&#xD;
&#xD;
          5. Platelet count &lt;100'000&#xD;
&#xD;
          6. Hospital admission for bleeding in previous 12 months&#xD;
&#xD;
          7. Stroke in previous 12 months&#xD;
&#xD;
          8. History of intracerebral hemorrhage&#xD;
&#xD;
          9. Severe chronic liver disease&#xD;
&#xD;
         10. Creatinine clearance &lt;40 ml/min&#xD;
&#xD;
         11. Cancer in previous 3 years&#xD;
&#xD;
         12. Planned major surgery in next 12 months&#xD;
&#xD;
         13. Glucocorticoids or NSAID planned for &gt;30 days after PCI&#xD;
&#xD;
         14. Expected non-adherence to &gt;30 days of dual antiplatelet therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiogenic shock&#xD;
&#xD;
          2. Major active bleeding at the time of PCI&#xD;
&#xD;
          3. Expected non-adherence with 1 month DAPT&#xD;
&#xD;
          4. Known intolerance to aspirin, clopidogrel, or ticagrelor&#xD;
&#xD;
          5. Inability to provide informed consent&#xD;
&#xD;
          6. Currently participating in another trial before reaching first endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Stefanini, MD, PhD</last_name>
      <phone>0282247384</phone>
      <email>giulio.stefanini@hunimed.eu</email>
    </contact>
    <investigator>
      <last_name>Giulio Stefanini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Reimers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Humanitas Hospital, Italy</investigator_affiliation>
    <investigator_full_name>Giulio Stefanini</investigator_full_name>
    <investigator_title>Assistant Professor of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

